BioSpace News Archive

Atsena Therapeutics today announced the appointment of Elisabeth (Lis) Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF as well as an analysis of patients hospitalized for heart failure with reduced ejection fraction.

Akero Therapeutics, Inc. announced it will present late-breaking oral and poster presentations on its lead product candidate efruxifermin (EFX) today at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2022 being held in Washington, D.C.

Organon is announcing the launch and product availability of Aybintio ® , a biosimilar of Avastin, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer.

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2022, on Monday, November 14, 2022, beginning at 4:30 p.m. ET.

Rallybio Corporation (Nasdaq: RLYB) today announced positive topline results from its Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announces its 2022 third quarter business results.

Better Therapeutics, Inc today announced it will release its third quarter 2022 financial results after the market closes on Monday, November 14, 2022.

Laborie Medical Technologies Corp, a specialist medical technology company, announced that the American Medical Association has issued the new Category 1 Current Procedural Terminology code 5X000 to report cystourethroscopy with mechanical urethral dilation and therapeutic drug delivery via coated balloon.

LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and analysis provider to the life sciences market, announced it has completed Series C round financing of $35 million to advance its mission of providing powerful, industry-leading methods of cellular analysis.